Skip to main content
Search

Promising medical therapies for Parkinson’s disease

Published on June 2, 2014   41 min

A selection of talks on Clinical Practice

Please wait while the transcript is being prepared...
0:00
My name is Dr. Robert Hauser. And I am Professor of Neurology and Director of the Parkinson's Disease and Movement Disorder Center at the University of South Florida in Tampa, Florida. I'll be talking about promising medical therapies for Parkinson's disease motor symptoms, including motor fluctuations and dyskinesias.
0:22
I'll review antiparkinsonian agents, including A2a antagonists, new levodopa preparations. I'll mention an inhaled formulation of apomorphine and safinamide, a mixed MAO-B glutamate inhibitor. I'll also talk about some anti-dyskinetic medications and development. So all the medications that I'll be talking about today are investigational and are not currently approved by FDA for use in the United States or by the regulatory authorities in Europe.
0:56
A2a, or adenosine 2a inhibitors, are technically non-dopaminergic medications, but they do interact with the dopamine system. In MPTP-lesioned parkinsonian primates, A2a inhibitors provide motor benefit with little or no development of dyskensia. In addition, in MPTP-lesioned levodopa-primed parkinsonian animals who express dyskinesia, A2a inhibitors improved motor function when added to levodopa without worsening dyskinesia. So in these animal models of both early and moderate to advanced Parkinson's disease, A2a inhibitors provide motor benefit without causing or worsening dyskinesia.

Quiz available with full talk access. Request Free Trial or Login.

Show
Hide

Promising medical therapies for Parkinson’s disease

Embed in course/own notes